Benefits
Prevention of acute radiation-induced dermatitis (Pivotal RCT)
A phase III RCT (n=254 breast cancer patients) compared calendula ointment vs trolamine (Biafine, the standard of care) applied 2x daily during postoperative breast radiation. Calendula significantly reduced grade >=2 acute dermatitis (41% vs 63%, p<0.001). Patients also had fewer interruptions in radiotherapy and reported milder pain (p=0.03). Strongest single piece of evidence for any topical intervention to prevent radiation dermatitis.
Wound healing support
Multiple smaller trials show calendula extracts/ointments accelerate wound healing in episiotomy, surgical wounds, venous leg ulcers, diabetic foot ulcers, and burn wounds. Effect size moderate; mechanism involves anti-inflammatory, angiogenic, and antimicrobial activities.
Diaper dermatitis treatment
An RCT of 66 children compared calendula vs aloe vera ointment for diaper dermatitis. Both treatments effective; calendula showed comparable efficacy. Reasonable evidence for pediatric topical use. Generally well-tolerated in this sensitive population.
Anti-inflammatory and mild antimicrobial topical use
Calendula's combination of triterpenoid faradiol monoesters (anti-inflammatory comparable to indomethacin in topical edema models), flavonoids, and saponins produces clinical anti-inflammatory effect on skin. Modest antimicrobial activity against bacterial and fungal skin pathogens. Useful for minor skin irritations, eczema flares, and inflammation. Less potent than topical corticosteroids but no steroid-related side effects.
Mechanism of action
Faradiol triterpenoid anti-inflammatory effect
The triterpenoid esters (especially faradiol-3-monoesters: laurate, myristate, palmitate) are the primary anti-inflammatory actives — comparable potency to indomethacin in murine ear edema models. Inhibit cyclooxygenase and lipoxygenase pathways. The acidic supernatant fraction containing carbon dioxide-extracted triterpenoids has strongest anti-inflammatory effect — water/ethanol extracts have lower activity.
Pro-angiogenic effect (wound healing)
Calendula stimulates angiogenesis and granulation tissue formation in wound healing models, promoting capillary growth into wound bed. Polysaccharide and triterpenoid fractions both contribute. Combined with anti-inflammatory effect, produces accelerated wound closure observed in clinical trials.
Antioxidant (carotenoid + flavonoid contribution)
Lutein, zeaxanthin, β-carotene (the yellow-orange color), and flavonoid glycosides provide combined antioxidant capacity. Reduces lipid peroxidation in inflamed skin. Less relevant for topical antioxidation than the direct anti-inflammatory effect, but contributes to overall therapeutic profile.
Antimicrobial activity (modest)
Calendula extracts inhibit Staphylococcus aureus, E. coli, Candida albicans, and several dermatophytes in vitro — modest activity, not comparable to dedicated antimicrobials. May contribute to wound healing benefit by reducing local infection risk but not primary mechanism.
Clinical trials
Phase III randomized controlled trial (Pommier P, Gomez F, Sunyach MP, D'Hombres A, Carrie C, J Clin Oncol 22(8):1447-1453, doi:10.1200/JCO.2004.07.063).
254 patients post-breast cancer surgery receiving postoperative radiation therapy at Centre Léon Bérard, France (-). Randomized to calendula ointment (Pommade au Calendula par Digestion, Boiron Ltd) n=126 or trolamine (Biafine, the institutional reference) n=128, applied to irradiated fields after each session.
Primary endpoint MET. Calendula significantly reduced occurrence of grade ≥2 acute dermatitis: 41% vs 63% (p<0.001) — a 22-percentage-point absolute reduction. Patients on calendula had fewer radiotherapy interruptions and reported milder pain (p=0.03). Conclusion: calendula was significantly superior to trolamine for preventing acute dermatitis during breast irradiation. Foundational evidence supporting calendula in radiation oncology supportive care; influential in international guidelines.
Randomized double-blind controlled clinical trial (Schneider F, Danski MT, Vayego SA 2015, Rev Esc Enferm USP 49(2):221-228, doi:10.1590/S0080-623420150000200006).
Radiation therapy patients randomized to calendula vs control for prevention/treatment of radiodermatitis.
Confirmed the findings of efficacy in radiodermatitis prevention and treatment, supporting calendula as evidence-based supportive care during cancer radiation therapy. Smaller and methodologically simpler than but provides replication evidence.
Randomized controlled trial (Siddiquee S, McGee MA, Vincent AD, Giles E, Clothier R, Carruthers S, Australas J Dermatol 62:e35-e40, doi:10.1111/ajd.13434).
82 women undergoing radiation therapy randomized to topical Calendula officinalis lotion (<5% v/v) vs Sorbolene standard of care (10% glycerine in cetomacrogol cream).
Mixed results in this Australian trial — calendula did not show statistically significant superiority over sorbolene standard of care for radiation dermatitis prevention in this cohort. Highlights that comparator choice matters: showed superiority over trolamine, while comparison vs more aggressive moisturizers (sorbolene) shows narrower margin. Net evidence: calendula is at least non-inferior to other topical therapies and significantly better than untreated/trolamine.